Improved Drug Eluting Stent for Percutaneous Coronary Intervention of the Left Main Artery in a Real World All-comers Population
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 May 2017
At a glance
- Drugs Everolimus (Primary) ; Antiplatelets
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms IDEAL-LM
- 01 May 2017 Rationale and study design, published in the American Heart Journal.
- 21 Mar 2016 Accrual to date is 26% as reported by United Kingdom Clinical Research Network.
- 11 Dec 2015 Accrual to date is 19% as reported by United Kingdom Clinical Research Network.